Fast Company Selects Biotech Companies as Part of Its 2019 List of Innovative...

快速公司选择生物技术公司作为其2019年创新名单的一部分。。。

2019-02-21 00:15:08 BioSpace

本文共1401个字,阅读需4分钟

For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted below. Foundation Medicine – In June 2018, sequencing diagnostics company Foundation Medicine came under the umbrella of Swiss pharma giant Roche in a $2.4 billion deal. Despite its acquisition, Foundation Medicine remains an autonomous company from Roche. It was selected for the Fast Company ranking for its innovative sequencing platform, which includes its approved F1CDx test that assesses all classes of genomic alterations in 324 genes known to drive cancer growth. In September, the company got Breakthrough Devices designation for a broad “liquid biopsy” test that analyzes blood for 70 genes tied to cancer growth, allowing doctors to monitor treatment response without doing invasive tissue samples, Fast Company said. Arterys – San Francisco-based Arterys was selected for its use of artificial intelligence to support clinical testing. In 2017, received approval from the U.S. Food and Drug Administration for its Arterys Cardio DL application. The Arterys technology is the first of its kind to receive U.S. approval that leverages cloud computing and deep learning in a clinical setting. The Arterys system provides automated, editable ventricle segmentations based on conventional cardiac MRI images that are as accurate as segmentations performed manually by experienced physicians, according to the company. Alnylam – Massachusetts-based Alnylam was placed on the list for being the first company to bring an RNAi treatment to market. The company won FDA approval in August 2018 for Onpattro (patisiran). The medicine is used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. hATTR amyloidosis is a rare disease that affects about 50,000 people worldwide. Recent studies suggest RNAi drugs could also target neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS, Fast Company said. Flatiron Health – Also snapped up by Roche in 2018, Flatiron Health developed its Health OncologyCloud platform that includes the industry-leading electronic medical record for oncology, advanced analytics, patient portal and integrated billing management. Its tech is an aggregating data resource that enables researchers to develop real-world insights into the ever-changing oncology landscape. Flatiron was founded by former Google employees Nat Turner and Zach Weinberg. When the deal with Roche was announced, Flatiron said it will continue its current business model, which contains a network of partnerships that includes partnerships with Celgene and Amgen. Amgen – Speaking of Amgen, the California-based company came in at number five on the Fast Company list of innovative biotechs. While Amgen is one of the biggest biotech companies in the world with a number of blockbuster treatments, such as Enbrel, Fast Company singled out one of its most recent FDA-approved treatments, Aimovig. The drug was co-developed by Amgen and Swiss pharma giant Novartis. Aimovig was approved for the preventive treatment of migraine in adults. The migraine medication was approved based off of stunning Phase III data that showed Aimovig reduced monthly migraine attacks in half. Aimovig was the first of a new class of anti-CGRP drugs to be approved for migraine treatment. Check out available jobs at Amgen! The other five biotech companies that made the Fast Company Top 10 list include Viz.ai, Velano Vascular, Berkley Lights, T2 Biosystems and Catalog.
在其2019年最具创新力的50家公司名单中, Fast Company 从生物技术行业中挑选了10家对患者治疗产生重大影响的公司。下文着重介绍前五项。 基础医学——2018年6月,测序诊断公司 Foundation Medicine 以24亿美元收购瑞士制药巨头罗氏公司( Roche )。尽管收购了 Foundation Medicine ,但仍是罗氏(Roche)的一家自主公司。它被选中为快速公司的创新测序平台排名,其中包括其批准的 F1CDx 测试,评估324个已知驱动癌症生长的基因的所有类别的基因组改变。Fast Company 表示,今年9月,该公司获得了 Breakthrough Devices 的称号,用于开展广泛的“液体活检”测试,对与癌症生长相关的70个基因的血液进行分析,使医生能够监控治疗反应,而不需要做侵入性组织样本。 Arterys ——总部位于旧金山的 Arterys 因使用人工智能支持临床测试而入选。2017年,获得美国食品药品监督管理局对其 Arterys Cardio DL 申请的批准。Arterys 的这项技术是首次获得美国批准,在临床环境中利用云计算和深度学习。根据该公司的说法, Arterys 系统提供了基于常规心脏 MRI 图像的自动、可编辑的心室分段,这些图像与经验丰富的医生手工进行的分割一样精确。 总部位于马萨诸塞州的 Alnyam 公司因是第一家将 RNAi 疗法推向市场的公司而被列入名单。公司于2018年8月获得了美国 FDA 对 Onpatro (天冬氨酸)的批准。该药物用于治疗成人遗传性转甲状腺素介导的淀粉样变性的多神经病。hATTR 淀粉样变性是一种罕见的疾病,影响到全世界约5万人。快速公司表示,最近的研究表明, RNAi 药物也可能针对神经退行性疾病,如老年痴呆症、帕金森病和 ALS 。 Flatiron Health ——2018年也被罗氏(Roche)收购, Flatiron Health 开发了其健康肿瘤云平台,包括肿瘤学行业领先的电子病历、先进分析、患者门户和综合计费管理。它的技术是一个聚合的数据资源,使研究人员能够发展对不断变化的肿瘤景观的现实世界的洞察力。Flatiron 由谷歌前雇员 NatTurner 和 ZachWeinberg 创立。与罗氏(Roche)的交易宣布后,弗拉蒂龙表示将继续其目前的商业模式,其中包括与新基(Celgene)和安进(Amgen)的合作伙伴网络。 安进-谈到安进(Amgen),这家总部位于加州的公司在快速公司的创新生物技术列表中名列第五。虽然安进(Amgen)公司是世界上最大的生物技术公司之一,有许多重磅治疗,如 Enbrel ,快速公司挑出了其最近 FDA 批准的治疗, Aimovig 。该药物是由安进(Amgen)和瑞士制药巨头诺华(Novartis)公司共同研发的。Aimovig 被批准用于成人偏头痛的预防性治疗。偏头痛药物是根据惊人的 III 期数据批准的,该数据显示 Aimovic 减少了每月偏头痛发作的一半。Aimovig 是首个获批用于偏头痛治疗的新型抗 CGRP 药物。在安进(Amgen)找工作! 其他五家生物科技公司跻身快速公司前十名,其中包括 Viz 。采购产品 ai , Velano 血管, Berkley 灯, T2生物系统和目录.

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文